Literature DB >> 8009568

Determination of fostriecin pharmacokinetics in plasma using high-pressure liquid chromatography assay.

L Pillon1, M J Moore, J J Thiessen.   

Abstract

Fostriecin is an antitumor antibiotic with marked activity against ovarian, breast, and lung cancer cell lines in the human tumor clonogenic assay. The mechanism of cytotoxicity in vivo is unknown; in vitro it has been shown to inhibit macromolecular synthesis, interact with the reduced folate carrier system, and inhibit topoisomerase II. Phase I testing of fostriecin in a daily for 5 days schedule has begun in cancer patients. A high-pressure liquid chromatographic method to measure fostriecin in plasma samples was developed using sulfaquinoxaline as an internal standard and ultraviolet detection (268 nm). The extraction efficiency is 70% and the sensitivity limit is 100 ng/ml. The pharmacokinetics of fostriecin were determined in six rabbits following intravenous injection of 12 mg/m2. The mean distribution space was 4.44 L/m2 and the mean plasma clearance was 302 ml/min/m2. The elimination half-life was 11.95 +/- 8.55 min. All rabbits exhibited a 10-60-fold increase in aspartate aminotransferase (AST) and alanine aminotransferase (ALT) that resolved within 48 h of drug administration.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8009568     DOI: 10.1097/00007691-199404000-00013

Source DB:  PubMed          Journal:  Ther Drug Monit        ISSN: 0163-4356            Impact factor:   3.681


  3 in total

1.  Suppression of Ser/Thr phosphatase 4 (PP4C/PPP4C) mimics a novel post-mitotic action of fostriecin, producing mitotic slippage followed by tetraploid cell death.

Authors:  Benjamin Theobald; Kathy Bonness; Alla Musiyenko; Joel F Andrews; Gudrun Urban; Xizhong Huang; Nicholas M Dean; Richard E Honkanen
Journal:  Mol Cancer Res       Date:  2013-05-13       Impact factor: 5.852

2.  Phase I and pharmacokinetic study of fostriecin given as an intravenous bolus daily for five consecutive days.

Authors:  Lyly H Lê; Charles Erlichman; Linda Pillon; Jake J Thiessen; Andrew Day; Nancy Wainman; Elizabeth A Eisenhauer; Malcolm J Moore
Journal:  Invest New Drugs       Date:  2004-04       Impact factor: 3.850

3.  Phase I and pharmacokinetic study of the topoisomerase II catalytic inhibitor fostriecin.

Authors:  R S de Jong; N H Mulder; D R Uges; D T Sleijfer; F J Höppener; H J Groen; P H Willemse; W T van der Graaf; E G de Vries
Journal:  Br J Cancer       Date:  1999-02       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.